Evercore ISI Lowers Repligen (NASDAQ:RGEN) Price Target to $130.00

Repligen (NASDAQ:RGEN - Get Free Report) had its target price decreased by investment analysts at Evercore ISI from $140.00 to $130.00 in a research report issued on Tuesday,Benzinga reports. The firm presently has an "in-line" rating on the biotechnology company's stock. Evercore ISI's price objective points to a potential upside of 1.12% from the company's previous close.

A number of other research analysts have also recently weighed in on RGEN. Wolfe Research upgraded shares of Repligen from a "peer perform" rating to an "outperform" rating and set a $160.00 price objective on the stock in a research report on Tuesday, April 29th. Royal Bank Of Canada dropped their price objective on Repligen from $202.00 to $189.00 and set an "outperform" rating for the company in a report on Wednesday, April 30th. Wall Street Zen cut Repligen from a "buy" rating to a "hold" rating in a report on Sunday, June 29th. Barclays started coverage on shares of Repligen in a research note on Tuesday, June 24th. They issued an "overweight" rating and a $150.00 price target on the stock. Finally, JPMorgan Chase & Co. reduced their price target on shares of Repligen from $200.00 to $190.00 and set an "overweight" rating on the stock in a research note on Tuesday, April 29th. Five equities research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $170.75.

Repligen Price Performance

Shares of NASDAQ RGEN traded up $4.13 during midday trading on Tuesday, reaching $128.56. The stock had a trading volume of 586,863 shares, compared to its average volume of 727,659. The stock has a 50-day moving average of $126.32 and a 200-day moving average of $139.73. The company has a debt-to-equity ratio of 0.27, a quick ratio of 5.79 and a current ratio of 6.79. The company has a market capitalization of $7.22 billion, a price-to-earnings ratio of -285.69, a price-to-earnings-growth ratio of 3.65 and a beta of 1.11. Repligen has a 12-month low of $102.97 and a 12-month high of $182.52.

Repligen (NASDAQ:RGEN - Get Free Report) last issued its earnings results on Tuesday, April 29th. The biotechnology company reported $0.39 earnings per share for the quarter, topping analysts' consensus estimates of $0.35 by $0.04. Repligen had a negative net margin of 3.93% and a positive return on equity of 4.53%. The firm had revenue of $169.17 million during the quarter, compared to analyst estimates of $163.65 million. During the same quarter in the prior year, the business earned $0.28 earnings per share. Repligen's revenue for the quarter was up 10.4% on a year-over-year basis. As a group, research analysts anticipate that Repligen will post 1.72 EPS for the current fiscal year.

Institutional Trading of Repligen

Hedge funds have recently added to or reduced their stakes in the stock. Signaturefd LLC grew its position in Repligen by 172.2% during the fourth quarter. Signaturefd LLC now owns 196 shares of the biotechnology company's stock worth $28,000 after buying an additional 124 shares during the period. Sava Infond d.o.o. acquired a new position in Repligen during the fourth quarter worth about $29,000. Raiffeisen Bank International AG acquired a new position in Repligen during the fourth quarter worth about $29,000. Twin Tree Management LP acquired a new position in Repligen during the first quarter worth $29,000. Finally, Itau Unibanco Holding S.A. acquired a new position in Repligen during the fourth quarter worth $40,000. 97.64% of the stock is owned by institutional investors and hedge funds.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.